Novel targeting peptide shows promise against COVID-19 cytokine storm
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
List view / Grid view
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
Researchers have created a method to promote the production of new antibiotic or antiparasitic compounds from the genomes of actinobacteria.
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
Scientists have revealed that four molecules found in the Ceramaster patagonicus starfish show potency against cancer in cell lines.
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.